Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)

Table 1 HPV Prevalence in 34 trials (N = 5681)

Title	Patients (n)	No. of HPV positive (n)	Prevalence HPV %	No. of HPV16 (n)	Prevalence HPV16 in HPV (%)
Mork rtl, et al. 2001	292	88	30.14%	35	39.77%
D'Souza, et al. 2007	100	40	40.00%	35	87.50%
Gillison, et al. 2000	253	62	24.51%	56	90.32%
Herrero, et al. 2003	1670	56	3.35%	21	37.50%
Smith, et al. 2004	201	46	22.89%	39	84.78%
Braakhuis, et al. 2004	143	24	16.78%	24	100.00%
Fakhry, et al. 2008	96	38	39.58%	36	94.74%
Teman, et al. 2008	105	12	11.43%	0	0.00%
Weinberger, et al. 2006	77	47	61.04%	47	100.00%
Licitra, et al. 2006	90	17	18.89%	17	100.00%
Worden, et al. 2008	66	27	40.91%	27	100.00%
Shindoh, et al. 1995	77	24	31.17%	24	100.00%
Lindel, et al. 2001	99	14	14.14%	11	78.57%
Klussmann, et al. 2001	98	25	25.51%	21	84.00%
Perrone, et al. 2007	77	16	20.78%	16	100.00%
Kutler, et al. 2003	25	21	84.00%	19	90.48%
Smith, et al. 2004	193	38	19.69%	33	86.84%
Baez, et al. 2004	118	52	44.07%	52	100.00%
Dahlgren, et al. 2004	110	12	10.91%	9	75.00%
Hoffmann, et al. 2004	73	28	38.36%	28	100.00%
Slebos, et al. 2006	36	8	22.22%	8	100.00%
Hammarstedt, et al. 2006	203	99	48.77%	86	86.87%
Ragin, et al. 2006	125	30	24.00%	30	100.00%
Reimers, et al. 2007	106	30	28.30%	29	96.67%
Furniss, et al. 2007	486	145	29.84%	145	100.00%
Smith, et al. 2008	301	81	26.91%	77	95.06%
Pintos, et al. 2008	72	14	19.44%	13	92.86%
Charfi, et al. 2008	52	32	61.54%	27	84.38%
Westra, et al. 2008	89	12	13.48%	12	100.00%
Hafkamp, et al. 2008	81	33	40.74%	33	100.00%
Friesland, et al. 2001	34	14	41.18%	14	100.00%
De Petrini, et al. 2006	47	20	42.55%	20	100.00%
Wittekindt, et al. 2005	34	18	52.94%	16	88.89%
Strome, et al. 2002	52	24	46.15%	21	87.50%
	5681	1247	21.95%	1081	86.69%